Navigation Links
Greenberg Traurig London Team Represents Long-time Client AstraZeneca AB in Two Divestment Agreements
Date:11/9/2018

The London office of global law firm Greenberg Traurig, LLP represented AstraZeneca AB on its agreement with Grünenthal to divest the European rights to Nexium for an upfront payment of USD700 million with further sales-related and milestone payments of up to USD90 million. Nexium (esomeprazole) is a proton pump inhibitor that decreases the amount of acid produced in the stomach. The law firm also represented AstraZeneca AB on its agreement with Grünenthal to divest the global rights to Vimovo in all markets excluding the US and Japan for an upfront payment of USD115 million and further payments up to another USD17 million. Vimovo combines the non-steroidal anti-inflammatory drug naproxen with esomeprazole, the active ingredient in Nexium, for patients a risk of developing ulcers.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Grünenthal is a science-based pharmaceutical company specialised in innovative pain management and related therapies. These divestments are part of several transactions in which Greenberg Traurig’s London office has represented AstraZeneca over the past eight years.

The deal was led by Adam McArthur and Warren Brown, in-house lawyers at AstraZeneca AB. Greenberg Traurig team members involved in these latest transactions included: Paul Maher, Vice Chair of Greenberg Traurig; Fiona Adams, Co-Managing Shareholder of the London office and the Co-Chair of the firm’s Global Corporate Practice; shareholders Henrietta Walker and Sarah Moyles; associates David Hirschman, Charlotte Irvine, Miles Daly, Eleni Pittas, and Declan Grady; and IP Consultant Ewen Mitchell.

“It has been an absolute pleasure to represent AstraZeneca and to work with Adam and Warren, its dynamic and commercially driven legal team,” Maher said. “We are proud to have been able to help them achieve AstraZeneca’s strategic divestment goals.”

About Greenberg Traurig’s Corporate Practice
Greenberg Traurig’s Corporate Practice comprises more than 450 lawyers in the United States, Europe, Asia, the Middle East and Latin America who regularly advise public and privately held companies, entrepreneurs and investment funds on global mergers and acquisitions, corporate restructurings, private equity and venture capital, underwritten and syndicated offerings, commercial finance and syndicated lending, cross-border transactions, and general corporate matters. The group’s industry experience includes transactions in a wide range of fields, from the pharmaceutical, medical devices, and life sciences fields, to representations involving clients in the aviation, banking, consumer products, energy, food and beverage, health care, manufacturing, media, technology, and telecommunications sectors.

About Greenberg Traurig’s London Office: Greenberg Traurig, LLP in London has established itself as a multidisciplinary law firm, with more than 80 lawyers and growing. The London office provides partner-led advice to domestic and international clients on a range of matters across the legal spectrum. Lawyers at Greenberg Traurig in London advise U.K. and multinational clients operating in many different sectors, including chemicals, pharmaceuticals, life sciences, energy, real estate, financial services, automotive, retail, and communications.

About Greenberg Traurig: Greenberg Traurig, LLP (GT) has more than 2,000 attorneys in 38 offices in the United States, Latin America, Europe, Asia, and the Middle East. GT has been recognized for its philanthropic giving, was named the largest firm in the U.S. by Law360 in 2017, and is among the Top 20 on the 2018 Am Law Global 100. Web: http://www.gtlaw.com; Twitter: @GT_Law.

Read the full story at https://www.prweb.com/releases/greenberg_traurig_london_team_represents_long_time_client_astrazeneca_ab_in_two_divestment_agreements/prweb15906696.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Archbishop Desmond Tutu Advocates St John International Charity Work on Packed London Visit and Audience with HM The Queen
2. UKs Flagship Health & Safety Event Has Successful Inaugural Year in London
3. genae Opens Offices in London
4. FDNA Partners with London Medical Databases (LMD) to Provide Long-Awaited Online Access to Leading Dysmorphology Database
5. Klinische Studie von LKC Technologies bestätigt kosteneffektive Alternative zum Goldstandard beim Screening auf diabetische Retinopathie. Einzelheiten werden beim EURETINA/ESCRS in London bekanntgegeben
6. NW BIO CEO TO PRESENT AT SMis 3rd ANNUAL CANCER VACCINES CONFERENCE IN LONDON
7. FDNA to Exhibit at ASHG2014 Presenting Face2Gene Integrated With London Medical Databases (LMD) Online
8. FDNA exposera sa solution Face2Gene intégrée en ligne avec London Medical Databases (LMD) à lASHG 2014
9. Process Validation in the US and EU (Workshop, London)
10. New Cancer Center at Guys Hospital in London to be Equipped with Varian TrueBeam Treatment Machines
11. TapImmune Appoints David Laskow-Pooley, CEO of London Pharma, to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... DIEGO (PRWEB) , ... July 17, 2019 , ... ... announced that DFree ®, the first wearable for urinary incontinence, will be ... University in Stanford, CA, on July 26, 2019. The Innovation Showcase recognizes startups ...
(Date:7/17/2019)... (PRWEB) , ... July 17, 2019 , ... ... September 11-13, in Phoenix, will provide strategies to keep pathologists, laboratory professionals and ... techniques to improve outcomes and enhance patient care. , Renowned Speakers Covering ...
(Date:7/17/2019)... ... 2019 , ... Steven C. Bilt, Chief Executive Officer of Smile Brands Inc. ... dental industry during a panel discussion at Dykema’s 6th Annual Definitive Conference for Dental ... Hotel in Dallas, Texas. , Bilt co-founded Smile Brands Inc. in 1998 and has ...
Breaking Medicine Technology:
(Date:7/19/2019)... FORT WASHINGTON, Pa. (PRWEB) , ... July 19, ... ... cardiovascular disease medical education, announces the hiring of Megan Clem as Senior Director ... pharmaceutical, medical device, and education sectors. , “Having worked globally with physician experts ...
(Date:7/18/2019)... (PRWEB) , ... July 18, 2019 , ... ... on addressing unmet needs in the field of urology, today announced that Garrett ... Center of Excellence. The designation recognizes that Dr. Matsunaga has achieved a high ...
(Date:7/18/2019)... ... ... Dr. Todd Britten says he and his staff try to keep up ... him by his patients. A recent news report highlighting a study that showed concerns ... in his Clearwater, Florida practice. Dental floss harmful studies (source: Harvard.edu) The ...
(Date:7/17/2019)... ... July 17, 2019 , ... ... that is capable of treating up to eight body areas simultaneously. Dr. Dennis ... muscle toning much faster and easier than previous muscle toning devices or conventional exercise. ...
(Date:7/17/2019)... ... 2019 , ... The Blackboard Catalyst Award in Teaching and ... honor is given to distance learning courses and programs that help set the ... from around the world that produce exemplary educational and training opportunities. Winners in ...
Breaking Medicine News(10 mins):